Tekla Life Sciences Investors

NYSE:HQL

Asset Management

Financial Services
$19.27 +0.62%

+$0.11 today

Market cap
$585.96M
Beta
0.73
P/E (TTM)
2.8
EPS (TTM)
$6.52
Dividend yield
11.35%
52W Low $12.34High $18.46

Volume 0.12M

Average 0.11M

HQL Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Tekla Life Sciences InvestorsNYSE: HQL

Gross Profit · Q2 FY2026 · quarter ended Mar 2026

Gross profit grows 186.8% year over year

Q2 FY2026 gross profit of $44.95M rose 186.8% year over year. Over 3 fiscal years it compounded at +48.6% a year.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025, unchanged from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$44.95M— QoQ
Last fiscal yearSep 2025
$86.39M-0.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+186.8%——
1 year-0.3%——
3-year CAGR+48.6%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
86.39M USD
Year-over-year change
-0.3%
4-year CAGR
+22.0%

Gross Profit vs competitors

How HQL compares with its peers on the latest reported figures

  • HQL's FY2025 gross profit of $86.39M is the 2nd highest of the 10 companies compared; the peer median is $47.71M.
  • Its year-over-year change of -0.3% is the 7th highest of 10, against a peer median of +9.6%.
  • Gross profit amounts to 100.0% of revenue for HQL, versus a peer median of 67.6%.
HQL Competitors Peer median
Gross Profit for HQL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ECCEagle Point Credit Company Inc.LTM Dec 2025$136.77M +209.3%—81.6%
HQLTekla Life Sciences InvestorsFY2025$86.39M -0.3%+48.6%100.0%
CCAPCrescent Capital BDC, Inc.LTM Mar 2026$83.47M +38.0%+73.9%66.9%
CIONCION Investment CorporationLTM Mar 2026$69.83M +2453.4%+34.8%47.3%
GAINGladstone Investment CorporationLTM Mar 2026$64.98M +5.4%-24.9%57.9%
GLADGladstone Capital CorporationLTM Mar 2026$47.71M -46.3%+84.7%67.6%
SORSource Capital, Inc.FY2025$44.07M +9.6%+46.2%93.3%
PNNTPennantPark Investment CorporationLTM Mar 2026$42.6M -25.2%—51.8%
MCIBarings Corporate InvestorsLTM Jun 2025$41.06M -1.3%+1.7%100.0%
TCPCBlackRock TCP Capital Corp.LTM Mar 2026-$18.71M +44.1%—76.5%
Peer median (excluding HQL) $47.71M+9.6%+40.5%67.6%

Competitors are the stored peer set for HQL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue45.02M31.86M39.39M86.69M86.39M
Cost of Revenue6.08M5.55M5.24M5.36M4.97M
Gross Profit38.95M26.31M18.28M86.69M86.39M
Gross Margin86.5%82.6%46.4%100.0%100.0%
Research & Development0(3)000
Selling, General & Admin844.02K1.08M903.14K1.33M743.17K
Operating Expenses1.16M1.35M1.17M1.39M791.57K
Depreciation & Amortization4.14M2.99M27.6M1.92M0
EBITDA68.68M(101.62M)49.95M87.22M85.59M
EBITDA Margin152.5%-318.9%126.8%100.6%99.1%
Operating Income64.53M(104.6M)(5.24M)85.3M85.59M
Operating Margin143.3%-328.3%-13.3%98.4%99.1%
Interest Income050.09K204.45K1.04M349.84K
Interest Expense00000
Other Income / Expenses(7.83K)2.42K27.6M87.22M0
Income Before Tax64.53M(104.6M)22.35M85.3M85.59M
Pre-Tax Margin143.3%-328.3%56.8%98.4%99.1%
Income Tax Expense00000
Net Income64.53M(104.6M)22.35M85.3M85.59M
Net Margin143.3%-328.3%56.8%98.4%99.1%
EPS (Basic)2.66(4.07)0.793.042.96
EPS (Diluted)2.66(4.07)0.793.042.96
Weighted Avg Shares24.26M25.68M28.29M28.06M28.87M
Weighted Avg Shares (Diluted)24.26M25.68M28.29M28.06M28.87M

Tekla Life Sciences Investors

NYSE:HQL

Intrinsic Alpha fair value

Locked

Current Price

$19.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.